Originalkatalog | Verfügbarkeit prüfen

1131P Overall survival after treatment with first-line crizotinib or alectinib in patients with stage IV NSCLC and ALK rearrangement: A real-world nationwide cohort study from the...

Tilkema-Tiebosch, M., Damhuis, R., Vijftigschild, S., Van Der Wekken, A.J.
Veröffentlicht in: Annals of Oncology ; volume 33, page S1068 ; ISSN 0923-7534;
2022